TOMAYIK Trademark

Trademark Overview


On Wednesday, March 10, 2021, a trademark application was filed for TOMAYIK with the United States Patent and Trademark Office. The USPTO has given the TOMAYIK trademark a serial number of 90571094. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 2, 2023. This trademark is owned by Bristol-Myers Squibb Company. The TOMAYIK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
tomayik

General Information


Serial Number90571094
Word MarkTOMAYIK
Filing DateWednesday, March 10, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 2, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 3, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 23, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Monday, October 2, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 2, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, February 28, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 3, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 3, 2023PUBLISHED FOR OPPOSITION
Wednesday, December 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, November 25, 2022NOTICE OF REINSTATEMENT E-MAILED
Wednesday, November 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 23, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, November 23, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, November 23, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, November 23, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, November 21, 2022REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED
Monday, November 21, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Monday, November 21, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, May 3, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, May 3, 2022FINAL REFUSAL E-MAILED
Tuesday, May 3, 2022FINAL REFUSAL WRITTEN
Wednesday, April 6, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 6, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 6, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, October 8, 2021NOTIFICATION OF PRIORITY ACTION E-MAILED
Friday, October 8, 2021PRIORITY ACTION E-MAILED
Friday, October 8, 2021PRIORITY ACTION WRITTEN
Tuesday, October 5, 2021ASSIGNED TO EXAMINER
Thursday, June 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 13, 2021NEW APPLICATION ENTERED